Primary Brain Tumor — Trials

Primary Brain Tumor — Trials · CancerIndex

Clinical trials

Registered studies

75 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 9
Ph III recruiting: 0
Growth YoY: —
Industry share: 7%
Top sponsor: Amsterdam UMC, location VUmc
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05092802	The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment	unknown	Phase 2	40	Shanghai Henlius BiotechINDUSTRY	1	May 3, 2022	clinicaltrials

Data updated 22 days agoSource updated May 3, 2022source: clinicaltrials